Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma

被引：0
作者：
Paludo, Jonas [1 ]
Vallumsetla, Nishanth [1 ]
Kumar, Shaji [1 ]
Ketterling, Rhett [1 ]
Gertz, Morie A. [1 ]
Dispenzieri, Angela [1 ]
Lacy, Martha Q. [1 ]
Buadi, Francis K. [1 ]
Dingli, David [1 ]
Painuly, Utkarsh [2 ,3 ]
Leung, Nelson [1 ]
Kyle, Robert [1 ]
Rajkumar, S. Vincent [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Hematol Univ Hosp Hradec Kralove, Dept Internal Med 4, Prague, Czech Republic
[3] Charles Univ Prague, Fac Med Hradec Kralove, Prague, Czech Republic
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Prognostic significance of t(11;14) expression by FISH in patients with newly diagnosed multiple myeloma in the era of novel therapies.
    Velez, Miguel Gonzalez
    Parrondo, Ricardo Daniel
    Andrews, Tracy
    Duma, Narjust
    Richter, Joshua Ryan
    Vesole, David H.
    Siegel, David Samuel DiCapua
    Biran, Noa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Integration of Novel Agents into the Care of Patients with Multiple Myeloma
    Orlowski, Robert Z.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5443 - 5452
  • [43] Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8;14)
    Li, Jian-yong
    Wang, Li-xia
    Shen, Wen-yi
    Lu, Shi-feng
    Chen, Li-juan
    Lu, Hua
    LEUKEMIA RESEARCH, 2009, 33 (04) : 584 - 586
  • [44] Impact of t(11;14) on the outcome of autologous transplantation in Multiple Myeloma: A multiple centers retrospective analysis from China
    Gao, Wen
    Du, Juan
    Liu, Junrun
    Zhou, Huixing
    Zhang, Zhiyao
    Jian, Yuan
    Yang, Guangzhong
    Wang, Guorong
    Fu, Weijun
    Li, Juan
    Chen, Wenming
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E205 - E206
  • [45] Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study.
    Durie, Brian G.
    Goldschmidt, Hartmut
    Mateos, Maria-Victoria
    Gonzalez, Veronica
    Du, Juan
    Kim, Kihyun
    Merlini, Giampaolo
    Mangiacavalli, Silvia
    Min, Chang Ki
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Ludwig, Heinz
    Esteves, Graca
    Handa, Hiroshi
    Escalante, Fernando
    de Larrea Rodriguez, Carlos Fernandez
    Delforge, Michel
    Cameron, Chris
    Rajkumar, S. Vincent
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMA
    Siskou, O.
    Terpos, E.
    Galanis, P.
    Vasilakopoulos, T.
    Tsirigotis, P.
    Batsis, I
    Megalakaki, A.
    Pouli, A.
    Konstantakopoulou, O.
    Karagkouni, I
    Kossiva, E.
    Kaitelidou, D.
    VALUE IN HEALTH, 2018, 21 : S33 - S33
  • [47] Novel Agents in Multiple Myeloma
    Szalat, Raphael
    Munshi, Nikhil C.
    CANCER JOURNAL, 2019, 25 (01) : 45 - 53
  • [48] Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma
    Pathak, Prajwol
    Unnikrishnan, Athira
    Zou, Fei
    Leather, Helen
    Cogle, Christopher R.
    Hsu, Jack W.
    Brown, Randy A.
    Wingard, John R.
    Norkin, Maxim
    BLOOD, 2016, 128 (22)
  • [49] The impact of response kinetics for multiple myeloma in the era of novel agents
    Yan, Yuting
    Mao, Xuehan
    Liu, Jiahui
    Fan, Huishou
    Du, Chenxing
    Li, Zengjun
    Yi, Shuhua
    Xu, Yan
    Lv, Rui
    Liu, Wei
    Deng, Shuhui
    Sui, Weiwei
    Wang, Qi
    Zou, Dehui
    Wang, Jianxiang
    Cheng, Tao
    Zhan, Fenghuang
    Tai, Yu-Tzu
    Yuan, Chenglu
    Du, Xin
    Qiu, Lugui
    Anderson, Kenneth C.
    An, Gang
    BLOOD ADVANCES, 2019, 3 (19) : 2895 - 2904
  • [50] Impact of Gain 1q21 (1q21+) in Patients with multiple Myeloma and Translocation t(11;14)
    Udovica, S.
    Scherbler, W.
    Fritz, P.
    Schneller, A.
    Ludwig, H.
    Zojer, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 144 - 144
12345